Compare IDAI & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDAI | PASG |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0M | 14.8M |
| IPO Year | 2022 | 2020 |
| Metric | IDAI | PASG |
|---|---|---|
| Price | $3.21 | $4.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $12.00 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 35.1K | 11.6K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 76.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $103.06 | N/A |
| Revenue Next Year | $140.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.17 | $3.29 |
| 52 Week High | $5.28 | $20.00 |
| Indicator | IDAI | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 56.02 | 54.00 |
| Support Level | $2.31 | $4.27 |
| Resistance Level | $3.47 | $4.95 |
| Average True Range (ATR) | 0.26 | 0.29 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 73.02 | 59.70 |
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The company operates in one reportable segment, artificial intelligence-powered solutions. The artificial intelligence-powered solutions segment generates revenue from software licenses, professional services, and recurring SaaS revenue.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.